-
MEXIDOL® (Emoxipine) 125 mg, 50 coated tablets
$17.00
$22.00 -
ARPEFLU (Umifenovir) 100 mg, 20/30 caps
$24.00 – $33.00
Kolofort 100s dispersing tablets oral
$16.90
Description
The instruction for medical use of KOLOFORT medicine the Trade name of the drug Kolofort Mezhdunarodnoye the unlicensed name Is not present the Dosage form of the Tablet dispersed Structure One tablet contains active agents in an oral cavity: Antibodies to human tumor necrosis factor an alpha affinely cleaned – 0.006 g *, Antibodies to mozgospetsifichesky protein S-100 affinely cleaned – 0.006 g *, Antibodies to a histamine affinely cleaned – 0.006 g * excipients: lactoses monohydrate, cellulose microcrystalline, magnesium stearate. * are applied on lactoses monohydrate in the form of mix of three active aqueous-alcoholic cultivations of the substance divorced respectively in 10012, 10030, 100200 times. The description of the Tablet of a ploskotsilindrichesky form, with risky and a facet, from white till almost white color. On the flat party from risky the inscription MATERIA MEDICA is put, on other flat party the inscription KOLOFORT is put. Pharmacotherapeutic group Drugs for treatment of functional disorders of intestines. The ATX A03AE code the Pharmacological Pharmacokinetics Sensitivity properties of modern physical and chemical methods of the analysis (gas-liquid chromatography, highly effective liquid chromatography, chromaTO-mass spectrometry) does not allow to estimate the maintenance of midget doses of antibodies in biological liquids, bodies and fabrics that makes technically impossible studying pharmacokinetics of the drug Kolofort. The pharmacodynamics Kolofort is the combined homeopathic medicine. It is experimentally shown that components of drug modify activity a ligand – receptor interaction of endogenous regulators with the corresponding receptors: antibodies to protein S-100 – to serotoninovy receptors and sigma to 1 receptors, antibodies to FNO-a – to receptor FNO-a, antibodies to a histamine – to localized in the digestive tract (DT) H4 – to histamine receptors. The combination of three active components allows to carry out combined effect on the central and peripheral links of pathogenesis of functional disturbances of intestines, including an abdominal pain syndrome. Antibodies to protein S-100 possess a wide range of psychotropic activity, including anxiolytic and antidepressive, anti-asthenic and nootropic effects that is clinically shown in elimination of internal tension, alarm, normalization of a number of visceral functions, including activity of a large intestine. Have no sedative effect, accustoming, a withdrawal. Antibodies to FNO-a have the significant anti-inflammatory effect, contribute to normalization of balance of pro-inflammatory and anti-inflammatory cytokines. Antibodies to a histamine have spasmolytic, anti-inflammatory, antiedematous effect. The combined use of components as a part of complex drug contributes to normalization of nervous and humoral control of function of intestines, decrease in visceral hypersensitivity of receptors of a large intestine to stretching, providing recovery of the broken motility of a GIT, to stopping of feeling of an abdominal distension and overflow of a stomach, reduction of expressiveness of a pain syndrome. Spasmolytic effect of drug is shown by relaxation of smooth muscles and reduction of a tone of a wall of a GIT, to decrease in endoluminal pressure, normalization of consistence of a chair, its frequency and the accompanying symptoms (stopping of imperative desires, tenezm, feelings of incomplete bowel emptying, additional efforts at the act of defecation, etc.). Indications Drug is used as a part of combination therapy at: – a syndrome of the angry intestines – functional disturbances of digestive tract. Route of administration and doses Inside. On one reception – 1 or 2 tablets (to hold in a mouth before full dissolution – not during meal). To accept 2 times a day. The course of treatment – 1-3 months, if necessary a course of treatment can be prolonged up to 6 months and/or to repeat in 1-2 months. Against the background of exacerbation of diseases the increase in frequency of reception up to 4 times a day for a period of 7 up to 14 days is possible. Side effects Are possible reactions of the increased individual sensitivity to drug components. The contraindication – the increased individual sensitivity to drug components – children’s and teenage age up to 18 years Medicinal interactions of Cases of incompatibility with other medicines is not revealed so far. Special instructions monohydrate in this connection patients are not recommended to appoint it with a congenital galactosemia, a sprue of glucose or a galactose, or in a congenital lactose intolerance is a part of drug lactoses. Pregnancy and the period of a lactation Safety of use of Kolofort for pregnant women and in the period of a lactation was not studied. In need of administration of drug it is necessary to consider a ratio risk/advantage. The feature of influence on ability to run the vehicle or other potentially dangerous Kolofort mechanisms does not influence ability of control of vehicles and other potentially dangerous mechanisms. Overdose of Cases of overdose it is not registered so far. At accidental overdose the dispepsichesky phenomena are possible. Treatment: symptomatic. A form of release and packing On 20 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil. On 5 blister strip packagings together with the instruction for medical use in the state and Russian languages place in a pack from cardboard. Storage conditions In the place protected from light, at a temperature not above 25 °C. To store out of children’s reach. 3 years not to apply a period of storage after an expiration date. Prescription status Without prescription the Producer/packer of LLC NPF MATERIA MEDIKA HOLDING, Russia, 127473, Moscow, 3rd Samotechny Lane, 9. Ph./fax: (495) 684-43-33. Holder of the registration certificate of LLC NPF MATERIA MEDIKA HOLDING, Russia. Production site of LLC NPF MATERIA MEDIKA HOLDING, Russia, 454139, Chelyabinsk, Buguruslanskaya St., 54. The name, the address and a contact information of the organization responsible for post-registration observation in the territory of RK: Representative office of LLC NPF MATERIA MEDIKA HOLDING in RK Almaty, Seyfullin St. 498, office 507. E-mail: kz@dep.materiamedica.ru the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products Representative office of LLC NPF MATERIA MEDIKA HOLDING in RK Almaty, Seyfullin St. 498, office 507. E-mail: kz@dep.materiamedica.ru
Reviews
There are no reviews yet.